The innovative pharmaceutical industry needs full support. It is the only true, remaining Belgian industry with global impact and still going strong. But it needs support.
Diminishing clinical studies, late and lesser reimbursements of approved innovative medicines are indicators of a need for urgent positive action by the Belgian federal government.
Without we will see negative impacts on patient healthcare, innovation, export and economic growth.
It should be high on the agenda of the negotiating parties for the next federal government.
N-VACD&VVooruitLes Engagés !Mouvement Réformateur (MR)Open Vld
🔈 🔉 🔊 We are excited to announce the upcoming panel discussion focusing on the relevance of sustainability in the pharmaceutical industry. Join us as we hear from pharmaceutical experts, including Hans Christian Eder from ZETA GmbH, as they share their insights and perspectives.
Check out the event details here ▶ : https://lnkd.in/dnPjtNaA
Be sure to mark your calendars and join us for this important conversation 👥.
#paneldiscussion#sustainability#pharmaceuticalindustry
As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry.
Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact Jeethendra.Kumar@fortrea.com if you are interested in joining one of two sessions.
#ClinicalResearch#PharmaceuticalInnovation#GlobalHealthcare#IndiaPharma#HealthcareLeadership#PartnershipModels#HealthcareEcosystem
As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry.
Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact Jeethendra.Kumar@fortrea.com if you are interested in joining one of two sessions.
#ClinicalResearch#PharmaceuticalInnovation#GlobalHealthcare#IndiaPharma#HealthcareLeadership#PartnershipModels#HealthcareEcosystem
As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry.
Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact Jeethendra.Kumar@fortrea.com if you are interested in joining one of two sessions.
#ClinicalResearch#PharmaceuticalInnovation#GlobalHealthcare#IndiaPharma#HealthcareLeadership#PartnershipModels#HealthcareEcosystem
As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry.
Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact Jeethendra.Kumar@fortrea.com if you are interested in joining one of two sessions.
#ClinicalResearch#PharmaceuticalInnovation#GlobalHealthcare#IndiaPharma#HealthcareLeadership#PartnershipModels#HealthcareEcosystem
As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry.
Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact Jeethendra.Kumar@fortrea.com if you are interested in joining one of two sessions.
#ClinicalResearch#PharmaceuticalInnovation#GlobalHealthcare#IndiaPharma#HealthcareLeadership#PartnershipModels#HealthcareEcosystem
As a pivotal player in the global pharmaceutical industry, India is showcasing its prowess in innovation and development, delivering significant value to patients around the world. Fortrea is holding two face-to-face sessions in India with senior executive leaders from across India’s pharmaceutical industry.
Share your insights on the latest advancements in data science and technology, explore new partnership models, and contribute to setting the blueprint for the future of both India’s pharmaceutical sector and the global healthcare ecosystem. Contact Jeethendra.Kumar@fortrea.com if you are interested in joining one of two sessions.
#ClinicalResearch#PharmaceuticalInnovation#GlobalHealthcare#IndiaPharma#HealthcareLeadership#PartnershipModels#HealthcareEcosystem
The topic of early access programs and how this strategy can be implemented prior to the broader commercialization of medicines is an important one that was covered in The Pharma Letter’s Expert View, by Er-Kim’s Mert Zorlular and Mihaela Vuksic, DBA.
By integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies.
Read the full article here: https://lnkd.in/e-_tCSRS
Thank you, Mert Zorlular and Mihaela Vuksic, DBA, for writing this insightful and much-needed article that highlights critical aspects of early access to novel medicines—a topic that is often misunderstood. Some of the key points I would like to emphasize in the article include:
1️⃣ Access Works Differently Outside “Core” Markets: Market access strategies in many international markets do not function the same way as they do in the U.S. or Western Europe and require a different approach.
2️⃣ Early Access is, In Most Cases, is not Easy Access: In these markets, products may be reimbursed, sold and supplied on a Named Patient basis, often with requirements, which is unlike similar programs in the Western context. But these programs are not “backdoors” to otherwise difficult markets, they are often part of a holistic policy approach and require close collaboration with the local payers, regulators and medical community, along with extensive compliance requirements.
3️⃣ Different Partners for Different Goals: If the main goal is to deliver products free of charge on a compassionate use basis, or to send a limited number of packs reactively, there are many alternatives that offer these services on a fee basis. (These are not outlined in our article and not part of Er-Kim’s business model.) While traditional EAPs in Western markets are often outsourced to companies that deliver this service, our partners work directly with us and alternative partners who cover other parts of the world, following the approach we discuss in The Pharma Letter.
Understanding these nuances is crucial for pharmaceutical companies aiming to provide life-saving treatments to patients worldwide. By integrating EAPs and other non-traditional strategies into our business models, we can ensure timely access to medicines for those who need them most.
The topic of early access programs and how this strategy can be implemented prior to the broader commercialization of medicines is an important one that was covered in The Pharma Letter’s Expert View, by Er-Kim’s Mert Zorlular and Mihaela Vuksic, DBA.
By integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies.
Read the full article here: https://lnkd.in/e-_tCSRS